News  |  Calendar  |  Positions

Pilot Project Program in Hemostasis and Vascular Biology (P3HVB)

The VMI was established at the University of Pittsburgh in 2008 as a home for rigorous, cutting edge, basic and translational research in hemostasis, red blood cell biophysics, transfusion medicine, cardiovascular biology, mitochondrial biology, and nitrite-nitric oxide and reactive oxygen species biochemistry in order to expand understanding of the control of blood flow to organ systems; with the ultimate goal of developing novel therapies for diseases such as pulmonary hypertension, sickle cell vasculopathy, atherosclerosis, hypertension, and heart disease.

Program Summary

The VMI Pilot Project Program in Hemostasis and Vascular Biology (P3HVB) is intended to attract investigators new to the general areas of hemostasis and vascular biology by seeding innovative and translational research projects that have the potential to open new avenues for critical research in the general areas of:

  • Hemostasis and platelet biology, especially as focused on the integration of the roles of red cells, platelets, and hemostatic factors
  • Hemophilia
  • Platelet Transfusion
  • Transfusion medicine
  • Transfusion-related lung injury (TRALI)
  • Small pilot clinical trials in above areas or vascular biology

The program will support grants of $25,000 for one year duration. Applications for new projects may request up to $50,000 with appropriate justification. If a previously awarded project is successful in demonstrating that the area of research is important and innovative, the investigator may apply for competitive renewals.

The due date for the FY23 cycle is April 15, 2022.

All University of Pittsburgh faculty members are eligible to apply as principal investigators.

Instructors, fellows, and postdoctoral researchers may also apply as principal investigators if they can demonstrate a track record of research success, if there is a research mentoring plan from a qualified faculty member at the rank of associate professor (not research track) or higher, and if there is a commitment from the faculty member in whose laboratory the instructor/fellow/postdoctoral researcher works that all necessary laboratory resources will be available for the proposed project see (here and below for relevant instructions). Collaboration between VMI member and non-VMI member investigators is encouraged.

For any given research group, only one award may be active at a given time. That is, if there are several research faculty members working under the umbrella and mentorship of a given faculty member, only one award may be active for the entire group, independent of whether the principal investigator on the P3HVB award is the senior investigator or any of the research faculty members.

Projects that focus on translational integrative vascular biology with an emphasis on the role of red cells, platelets, and hemostatic factors will be of high priority, although other areas of research will be considered. Collaborative efforts, bringing new researchers into the critical research areas described previously will be given additional priority and should be highlighted as part of the proposal. Should other funding sources become available for the P3HVB, the relative priority on the role of red cells, platelets, and hemostatic factors will be commensurate with the relative levels of funding from and priorities of the other sources. Independent of the source of funding, translational research will be of the highest priority. Thus, it will be incumbent on an applicant to convince reviewers that the results of a laboratory-based program have the potential to be translated into clinical utility. Applications from early-career investigators and those with a particularly strong need for funding will be prioritized.

Budget Information
In planning budgets, please note that requests for no-cost extensions (carryovers) will need to be justified in detail. Approval will be contingent upon demonstration of significant progress in the conduct of the project and on evaluation of the reasons for the delay in its completion. If an award is to be made, no monies can be expended until any necessary regulatory protocols (IRB, IACUC, rDNA, CORID, hSCRO) are approved. The start date for the project will be dependent on such approval.
Application Elements

Applications must include:

  • Cover Page – name of faculty PIs, academic degrees, departments, contact information, budget period (not to exceed one year and to start four weeks after submission date at earliest), requested budget (not to exceed $50K)
  • Proposal – Maximum of 3 pages (+ 1-page bibliography) narrative addressing research rationale, aims/hypotheses, approach, expected results and plan for extramural funding
  • Budget – one-page budget describing distribution of funds. Note:
    – Money can be used to support staff and postdocs, but not faculty salaries
    – Money cannot be used to buy major equipment
    – Money can support only direct costs (no indirect costs)
  • If the principal investigator is an instructor, fellow, or postdoctoral researcher, a letter of support from the research mentor that documents the relevant mentoring plan must be included. If the research mentor is someone other than the faculty member in whose laboratory the applicant has a primary appointment, there must also be a letter from the faculty member with primary responsibility for the applicant that documents that all necessary resources for conducting the project are available to the applicant. Demonstration of an appropriate mentoring plan and of the availability of necessary resources will be some of the criteria used in evaluating the application.
Review Criteria

The primary review criteria are:
• The degree to which the project explores the role of red cells, platelets and hemostatic factors
• The potential to lead to more comprehensive studies
• The degree to which the project is translational
• The scientific feasibility and scientific merit of the project
• That the letter(s) of support for instructors, fellows, or postdoctoral researchers demonstrate(s) adequate commitment to the applicant and to the project.

Applications will undergo peer review by non-conflicted investigators from the University of Pittsburgh or UPMC. Recommendations made as a result of the peer review process will be forwarded to the internal advisory board of the VMI for final selection of grants to be awarded. Successful applicants will be expected to present their findings, both in written form and through presentation, to the VMI.

Applications are to be submitted electronically, as a single pdf file, to Andy Stephany, Administrator VMI,, with a cc to by 5:00 pm on the receipt date identified above. No exceptions will be made to the receipt date. Within one week of the receipt date, each applicant should receive an e-mail message from Andy notifying him/her that his/her application has been received. If an applicant does not receive such notification, he/she should contact Andy.

Questions about the program should be directed to Stephen Chan, MD, PhD, FAHA, Director, VMI,

Awarded Grants

Recently Funded


InvestigatorProject TitleSponsorStatus
William Bain, MDCompetitive Renewal: “Platelets counter lung epithelial cell death to protect against infection-induced lung injury”HCWPActive
Stephen Chan, MD, PhDDevelopment of 18F-fluoroglutamine as a novel metabolic tracer for PET imaging in pulmonary hypertensionVitalantActive
Jacqueline Ho, MDEndothelial miR-17~92 protects against renal ischemia-reperfusion injuryVitalantActive
Prithu Sundd, PhDRole of platelet extracellular vesicles in PH pathogenesisHCWPActive
Sina Tavakoli, MD, PhDTargeted Imaging of CMKLR1 for Detection of Inflammation in Human Endarterectomy SpecimensVitalantActive
William Bain, MDPlatelets counter lung epithelial cell death to protect against infection-induced lung injuryHCWPActive
Partha Dutta, DVM, PhDRole of platelet-derived microvesicles in inflammatory myeloid cell generation after myocardial infarctionHCWPActive
Ram Kalpatthi, MDNovel Biomarker of neurocognitive function in children and adults with sickle cell diseaseVitalantActive
Bernhard Kühn, MDInjury-induced vascular signals inhibit heart regenerationVitalantActive
Toru Nyunoya, MDRole of neutrophil-platelet aggregates in COPD exacerbationHCWPActive
Michael Risbano, MDmiRNA and Myokines Acutely-expressed During Exercise (M2ADE)VitalantActive
Craig Seaman, MD, MSNormalized von Willebrand factor levels in type 1 von Willebrand disease and risk of bleeding with invasive proceduresHCWPActive
Dario Vitturi, PhDTryptophan Metabolism Imbalance in Sickle Cell DiseaseVitalantActive
Katherine Wood, PhDA Potential Mechanism of Resistance to Prophylactic Transfusion Against Stroke in Sickle Cell DiseaseVitalantActive
Previously-Funded P3HVB Grants
Investigator(s)Project TitleSponsorStatus
Carlton Bates, MDVascular development and blood flow in normal and FGF receptor mutant bladdersHCWPActive
Justin Buland, DONovel Biosynthesis of Lipid Mediators and their effects on Pulmonary Endothelium in ALIITxMActive
(Bill?) ChenMiR-34a regulation of tetrahydrobiopterin in angiogenesisITxMActive
Kathleen Dorritie, MDDevelopment of a joint pediatric sickle cell allogeneic hematopoetic stem cell transplantation program: Innovation, Research, and High Quality Patient CareITxMActive
Hernando Gomez Danies, MDThe goal of glycocalyx shedding and platelet adhesion in sepsis-induced microvascular dysfunctionHCWPActive
Arun Jeyabalan, MDAsymmetric Dimethylarginine, Arginase and Nitric Oxide in the Prediction and Pathogenesis of PreeclampsiaITxMActive
Daniel Kass, MDTGFB regulates expression of the relaxin receptor RXFP1 in Pulmonary Arterial HypertensionHCWPActive
Janet Lee, MD, MSRole of Red Cell Microparticles in Altering Innate Immune Response Following TransfusionITxMActive
(Christine?) LeeperRapid thromboelastography (TEG) in pediatric trauma: Delineation and management of trauma-induced coagulopathyHCWPActive
Mason (Radiology)PET imaging of the vaso-occlusive crisis of sickle cell diseaseHCWPActive
Matthew Neal, MDPlatelet derived microparticles promote post-traumatic deep vein thrombosis formationHCWPActive
Seyed Nourai, MD, PhDRisk of 30-day readmission among sickle cell disease patients, application of electronic medical recordITxMActive
Sanjay Patel, MD, MSUsing electronic health records to assess the impact of obstructive sleep apnea on risk of incident pulmonary hypertensionITxMActive
Caterina Rosano, MD, MPHNeurovascular Signature of Accelerated Cognitive Impairment in Adult Patients with Sickle Cell DiseaseITxMActive
Sunder Sims-Lucas, PhDThe renal microvasculature is highly sensitive to hyperglycemiaITxMActive
Richard Steinman, MD, PhDCell Cycle Proteins as Novel Modulators of Platelet FunctionHCWPActive
Ora Weisz, PhDVinDCate: Vitamin D in sickle cell patientsITxMActive
AhmadThe Role of Platelet Gene Expression in the Pathogenesis of Pulmonary Arterial HypertensionHCWPCompleted
Badylak/GilbertCD47 blockade enhances angiogenesis in decellularized organsITxMCompleted
Bauer*Complement Activation and Thrombosis in Pulmonary Hypertension*HCWPCompleted
BauerCross talk between TLR4 and the complement system contributes to the pathogenesis of pulmonary hypertensionHCWPCompleted
Bayir/Kim-CampbellCardiopulmonary bypass and organ dysfunction: association with hemolysis and cell-free hemoglobinITxMCompleted
BelferExploratory studies of psychophysical pain phenotyping and genetic variability in children with sickle cell diseaseITxMCompleted
BiselloEBP50 and atherosclerosisHCWPCompleted
BodnarModulation of Endothelial Cell Function - Regulation by Platelet ActivationHCWPCompleted
GeorgeHIV Nef and Src Kinase Signaling in HIV-Associated Pulmonary Arterial HypertensionHCWPCompleted
HughanAn Open-Label Study of Oral Combination of Nitrite and Nitrate in Adults with Metabolic Syndrome and HypertensionITxMCompleted
KelleyStorage-Induced Hemolysis of Packed Red Blood Cells Results in Direct and Indirect ROS Production and NO InactivationHCWPCompleted
KhandharThe Study of Pulmonary Hypertension in Patients with Left Heart Failure Utilizing Novel Vascular Biology TechniquesHCWPCompleted
KimRegulation of Platelet Biology and Thombosis by Histone DeacetylasesHCWPCompleted
LeeRed Cell Microparticles in Transfusion-Related Lung Inflammatory InjuryITxMCompleted
McLaughlin/KaynarRegulation of Endothelial Function by Coagulation Proteases in SepsisITxMCompleted
McVerryThe Role of Endothelial Dysfunction in Transfusion Related Acute Lung InjuryITxMCompleted
McVerryInteraction between Nox2 and eNOS contributes to pulmonary vascular dysfunction in acute lung injuryITxMCompleted
O'DonnellImpaired vascular blood flow to skeletal muscle in hyperglycemic sepsisITxMCompleted
RagniPhase II Biologic Effects Study of Recombinant Interleukin-11 (rhiL-11, Neumega®) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVPHCWPCompleted
RagniThrombin generation and hemomstasis in the international immune tolerance study: ITI TGT SubstudyHCWP
RojasModification of perfusion solution to improve the quality of ex vivo human lungsHCWPCompleted
Sims-LucasDetermining the role of stromally derived endothelium during organogenesisITxMCompleted
TillmanDepletion of Circulating Progenitors to Prevent Vascular RestenosisHCWPCompleted
TofovicAdenosine Deaminase - Adenosine Pathway in Hemolysis-Associated Pulmonary HypertensionHCWPCompleted
YangPatient-Specific Induced Pluripotent Stem Cells as a Model for Inherited Pulmonary Arterial HypertensionITxMCompleted
*March 2012 - Dr. Eileen Bauer was awarded the Entelligence Young Investigator Award in pulmonary vascular disease. Her submission was based on work funded by this VMI P3HVB grant.